Pasar al contenido principal

COMPLEMENT SYSTEM DYSREGULATION IN DISEASE

RYC-2013-13395

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Factor H competitor generated by gene conversion events associates with atypical hemolytic uremic syndrome

  • Goicoechea de Jorge, Elena
  • Tortajada, Agustín
  • Pinto, Sheila
  • Gastoldi, Sara
  • Martín Merinero, Héctor
  • García-Fernández, Jesús
  • Arjona, Emilia
  • Cao, Mercedes
  • Remuzzi, Giuseppe
  • Noris, Marina
  • Rodríguez de Córdoba, Santiago
10 p.-6 fig.-1 tab., Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy caused by complement pathogenic variants, mainly affects the kidney microvasculature. A retrospective genetic analysis in our aHUS cohort (n=513) using multiple ligation probe amplification uncovered nine unrelated patients carrying a genetic abnormality in the complement factor H related 1 gene (CFHR1) that originates by recurrent gene conversion events between the CFH and CFHR1 genes. The novel CFHR1 mutants encode an FHR-1 protein with two amino acid substitutions, L290S and A296V, converting the FHR-1 C terminus into that of factor H (FH). Next-generation massive-parallel DNA sequencing (NGS) analysis did not detect these genetic abnormalities. In addition to the CFHR1 mutant, six patients carried the previously uncharacterized CFH-411T variant. In functional analyses, the mutant FHR-1 protein strongly competed the binding of FH to cell surfaces, impairing complement regulation, whereas the CFH-411T polymorphism lacked functional consequences. Carriers of the CFHR1 mutation presented with severe aHUS during adulthood; 57% of affected women in this cohort presented during the postpartum period. Analyses in patients and unaffected carriers showed that FH plasma levels determined by the nonmutated chromosome modulate disease penetrance. Crucially, in the activated endothelial (HMEC-1) cell assay, reduced FH plasma levels produced by the nonmutated chromosome correlated inversely with impairment of complement regulation, measured as C5b-9 deposition. Our data advance understanding of the genetic complexities underlying aHUS, illustrate the importance of performing functional analysis, and support the use of complementary assays to disclose genetic abnormalities not revealed by current NGS analysis., S.R.d.C. is supported by the Spanish “Ministerio de Economía y Competitividad-Federación Española de Enfermedades Raras (FEDER)” (SAF2015-66287R), the Seventh Framework Programme European Union Project EURenOmics (305608), and the Autonomous Region of Madrid (S2010/BMD-2316). S.R.d.C. is member of the “Centro de Investigaciones Biológicas Intramural Program “Molecular Machines for Better Life” (MACBET).” E.G.d.J. is supported by the Spanish “Ministerio de Economía y Competitividad” (RYC-2013-13395 and SAF2014-52339P). M.N. is supported by the Seventh Framework Programme European Union Project EURenOmics (305608). This study was also partially supported by Redes Tematicas De Investigacion Cooperativa En Salud, Red de Investigación Renal (RD06/0016/1002 and RD12/0028), the Instituto de Salud Carlos III, and the Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mycophenolate Mofetil in C3 glomerulopathy and pathogenic drivers of the disease

  • Caravaca-Fontán, Fernando
  • Díaz-Encarnación, Montserrat M.
  • Lucientes, Laura
  • Cavero, Teresa
  • Cabello-Chaves, Virginia
  • Ariceta, Gema
  • Quintana, Luis F.
  • Marco, Helena
  • Barros, Xoana
  • Ramos, Natalia
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema
  • Rodríguez, Adela
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Lumbreras, Javier
  • Allende, Natalia
  • Sánchez de la Nieta, María Dolores
  • Rodríguez, Eva
  • Olea, Teresa
  • Melgosa, Marta
  • Huerta, Ana
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga, Gloria
  • de Lorenzo, Alberto
  • Cano-Megías, Marta
  • González, Fayna
  • Shabaka, Amir
  • López-Rubio, María Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, L.
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
  • Praga, Manuel
12 p.-4 fig.-4 tab., BACKGROUND AND OBJECTIVES: C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was associated with improved outcomes, although the genetic profile of these patients was not systematically analyzed. This study aims to analyze the main determinants of disease progression and response to this therapeutic regimen., DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective, multicenter, observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy (n=81) or dense deposit disease (n=16) between January 1995 and March 2018 were enrolled. Multivariable and propensity score matching analyses were used to evaluate the association of clinical and genetic factors with response to treatment with corticosteroids and MMF as measured by proportion of patients with disease remission and kidney survival (status free of kidney failure)., RESULTS: The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this treatment was associated with a higher rate of remission and lower probability of kidney failure (79% and 14%, respectively) compared with patients treated with other immunosuppressives (24% and 59%, respectively), or ecluzimab (33% and 67%, respectively), or conservative management (18% and 65%, respectively). The therapeutic superiority of corticosteroids plus MMF was observed both in patients with complement abnormalities and with autoantibodies. However, patients with pathogenic variants in complement genes only achieved partial remission, whereas complete remissions were common among patients with autoantibody-mediated forms. The main determinant of no remission was baseline proteinuria. Relapses occurred after treatment discontinuation in 33% of the patients who had achieved remission with corticosteroids plus MMF, and a longer treatment length of MMF was associated with a lower risk of relapse., CONCLUSIONS: The beneficial response to corticosteroids plus MMF treatment in C3 glomerulopathy appears independent of the pathogenic drivers analyzed in this study., Work in this study was supported by the Instituto de Salud CarlosIII/ Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grant PI16/01685 and Red de Investigación Renal (RedInRen) (RD12/0021/0029) (to M. Praga), and the Autonomous Region of Madrid (S2017/BMD-3673) (to S. Rodríguez de Córdoba and M. Praga).E. Goicoechea de Jorge is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades” (RYC-2013-13395 and RTI2018-095955-B-100). S. Rodríguez de Córdoba is supported by Ministerio de Economía y Competitividad/FEDER grant SAF2015-66287R and Autonomous Region of Madrid grant S2017/BMD3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases, Short title: Molecular understanding of FHR-1 function

  • Martín Merinero, Héctor
  • Subías, Marta
  • Pereda, Amaia
  • Gomez-Rubio, Elena
  • Juana-López, Lucía
  • Fernández Rivera, Constantino
  • Goicoechea de Jorge, Elena
  • Martín-Santamaría, Sonsoles
  • Cañada, F. Javier
  • Rodríguez de Córdoba, Santiago
33 p.-7 fig., Factor H-related proteins (FHRs) are a group of partly characterized complement proteins that are thought to promote complement activation by competing binding of factor H (FH) to surface-bound C3b. Among them, FHR-1 is remarkable because is associated with atypical hemolytic uremic syndrome (aHUS) and other important diseases. Using a combination of biochemical, immunological, nuclear magnetic resonance and computational approaches, we have characterized a series of FHR-1 mutants (including two associated with aHUS) and have unraveled the molecular bases of the so-called de-regulation activity of FHR-1. In contrast with FH,FHR-1 lacks the capacity to bind sialic acids, which prevents C3b-binding competition between FH and FHR-1 in host cell surfaces. aHUS-associated FHR-1 mutants are pathogenic because they have acquired the capacity to bind sialic acids, which increases FHR-1 avidity for surface-bound C3-activated fragments and results in C3b-binding competition with FH. FHR-1 binds to native C3, in addition to C3b, iC3b and C3dg.This unexpected finding suggests that the mechanism by which surface-bound FHR-1 promotes complement activation is the attraction of native C3 to the cell surface. Whilst C3b-binding competition with FH is limited to aHUS-associated mutants, all surfacebound FHR-1 promote complement activation, which is delimited by the FHR-1/FH activity ratio. Our data indicate that the FHR-1 de-regulation activity is important to sustain complement activation and C3 deposition at complement activating surfaces.They also support that abnormally elevated FHR-1/FH activity ratios would perpetuate a pathological complement dysregulation at complement activating surfaces, which may explain the association of FHR-1 quantitative variations with diseases., SRdeC, FJC and SMS are supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” grants (SAF2015-66287-R, RTI2018-094751-B-C22, and CTQ2017-88353-R, respectively) and the Autonomous Region of Madrid (S2017/BMD-3673). EGdeJ is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades-FEDER (RYC-2013-13395 and RTI2018-095955-B-100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

  • Caravaca-Fontán, Fernando
  • Díaz-Encarnación, Montserrat M.
  • Cabello, Virginia
  • Ariceta, Gema
  • Quintana, Luis F.
  • Marco, Helena
  • Barros, Xoana
  • Ramos, Natalia
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema
  • Rodríguez, Adela
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia
  • Sánchez de la Nieta, María Dolores
  • Rodríguez, Eva
  • Olea, Teresa
  • Melgosa, Marta
  • Huerta, Ana
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga, Gloria
  • de Lorenzo, Alberto
  • Draibe, Juliana
  • Cano-Megías, Marta
  • González, Fayna
  • Shabaka, Amir
  • López-Rubio, María Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, L.
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
  • Praga, Manuel
  • Spanish Group for the Study of Glomerular Diseases (GLOSEN)
11 p.-4 fig.-4 tab., Introduction: The association between a change in proteinuria over time and its impact in kidney prognosis has not been analyzed in C3 glomerulopathy. This study aims to investigate the association between the longitudinal change in proteinuria and the risk of kidney failure., Methods: Retrospective, multicenter observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. A joint modeling of linear mixed-effects models was applied to assess the underlying trajectory of a repeatedly measured proteinuria, and a Cox model to evaluate the association of this trajectory with the risk of kidney failure., Results: The study group consisted of 85 patients, 70 C3 glomerulonephritis and 15 dense deposit disease, with a median age of 26 years (range 13-41). During a median follow-up of 42 months, 25 patients reached kidney failure. The longitudinal change in proteinuria showed a strong association with the risk of this outcome, with a doubling of proteinuria levels resulting in a 2.5-fold increase of the risk. A second model showed that a ≥ 50% proteinuria reduction over time was significantly associated with a lower risk of kidney failure (HR: 0.79; 95% CI : 0.56-0.97; p < 0.001). This association was also found when the ≥50% proteinuria reduction was observed within the first 6 and 12 months of follow-up., Conclusion: The longitudinal change in proteinuria is strongly associated with the risk of kidney failure. The change in proteinuria over time can provide clinicians a dynamic prediction of kidney outcomes., This study was supported by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grant PI16/01685 and PI19/1624, and Red de Investigación Renal (RedInRen) (RD12/0021/0029) (to M.P.), the Autonomous Region of Madrid (S2017/BMD-3673) (to M.P.); E.G.d.J. was supported by the Spanish ‘Ministerio de Ciencia, Innovación y Universidades’ (RYC-2013-13395 and RTI2018-095955-B-100); S.R.d.C. was supported by Ministerio de Economía y Competitividad/FEDER grant SAF2015-66287R and Autonomous Region of Madrid grant S2017/BMD3673., Peer reviewed